The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLIX.f

Anaphylaxis-Anaphylactoid reaction (can be fatal)

Publications

Uyanikoglu A, Ermis F, Akyuz F, Pinarbasi B, Baran B, Aydogan T, Demir K, Besisik F, Kaymakoglu S

Infliximab in inflammatory bowel disease: attention to adverse events.

European review for medical and pharmacological sciences 2014 Aug;18;2337-42 — 2014 Aug — 2337-42

Hamzaoglu H, Cooper J, Alsahli M, Falchuk KR, Peppercorn MA, Farrell RJ

Safety of infliximab in Crohn's disease: a large single-center experience.

Inflammatory bowel diseases 2010 Dec;16;2109-16 — 2010 Dec — 2109-16

Chávez-López MA, Delgado-Villafaña J, Gallaga A, Huerta-Yáñez G

Severe anaphylactic reaction during the second infusion of infliximab in a patient with psoriatic arthritis.

Allergologia et immunopathologia 2005 Sep-Oct;33;291-2 — 2005 Sep-Oct — 291-2

Stallmach A, Giese T, Schmidt C, Meuer SC, Zeuzem SS

Severe anaphylactic reaction to infliximab: successful treatment with adalimumab - report of a case.

European journal of gastroenterology & hepatology 2004 Jun;16;627-30 — 2004 Jun — 627-30

Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, Plevy S

The incidence and management of infusion reactions to infliximab: a large center experience.

The American journal of gastroenterology 2003 Jun;98;1315-24 — 2003 Jun — 1315-24